Topic
Topic
A plaintiff alleges dupilumab caused cutaneous T-cell lymphoma, a rare non-Hodgkin lymphoma that mimics eczema. The complaint triggers fresh review of the IL-4/IL-13 inhibitor's safety profile.
Sanofi will pay $1 billion to expand its Regeneron alliance and fund a next-generation successor to Dupixent, doubling down on th…
Attorneys are competing for leadership posts in the Dupixent MDL, where plaintiffs allege Sanofi and Regeneron failed to warn abo…
Sanofi and Regeneron renew their Dupixent alliance ahead of the patent cliff, AstraZeneca commits $2B to Summit, and Lilly report…
Sanofi will pay Regeneron $1 billion upfront, plus up to $7 billion in milestones, to co-develop four long-acting antibodies targ…
